A Distinct Human Papilloma Virus Epidemiological Profile of Korean-Chinese Women Living in Yanbian, China

Cervical cancer is a common in women worldwide. Human papilloma virus (HPV), which is known to be a direct cause of cervical cancer, differs in its infection rate and genotype by country, geography, race, genetic factors, and immune status. No previously reported studies have reported the HPV prevalence and genotype distributions of Korean-Chinese women living in China. This study examined the prevalence and genotype distribution of HPV among Korean-Chinese women to find similarities and differences compared to Han-Chinese women and Korean women. We also evaluated the effectiveness of a genotyping test compared with liquid-based cytology (LBC) as a screening test. We performed LBC and HPV genotyping tests on 2099 women living in the Yanbian region. The mean age of the 2099 subjects was 42.5 years (18-82). The largest ethnic groups were Han-Chinese (78%), Korean-Chinese (20.2%), Man-Chinese (0.8%), Jang-Chinese (0.04%), and Myo-Chinese (0.04%). Of the Korean-Chinese women, 34.4% tested positive for HPV; the most prevalent subtypes were 52, 58, 16, 53, and 33, which was clearly different from those of Han-Chinese women and other Koreans. The results of LBC showed a false negative rate of 62.4% compared with the results of HPV genotyping tests. This shows that a cervical cancer screening system utilizing HPV genotyping or a combined method is more effective. According to the HPV profile, only the Gardasil 9 vaccine can cover the HPV subtypes prevalent in Korean-Chinese women in the Yanbian region. This paper is the first report on HPV epidemiology among Korean-Chinese women in China.

Human papilloma virus; Uterine cervical neoplasm; HPV genotyping; Vaccine.

[1] Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A.: “Global cancer statistics, 2012”. Ca. Cancer J. Clin., 2015, 65, 87- 108.

[2] Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. the Journal of Pathol-ogy, 1999, 189, 12-19.

[3] Woodman C.B., Collins S., Winter H., Bailey A., Ellis J., Prior P., et al.: “Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study”. the Lancet, 2001, 357, 1831-1836.

[4] Castle P.E., Wacholder S., Sherman M.E., Lorincz A.T., Glass A.G., Scott D.R., et al.: “Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women”. Cancer, 2002, 95, 2145-2151.

[5] Rozendaal L., Walboomers J.M.M., van der Linden J.C., Voorhorst F. J., Kenemans P., Helmerhosrt T.J.M., et al.: “PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears”. Int. J. Cancer, 1996, 68, 766-769.

[6] Ylitalo N., Sørensen P., Josefsson A. M., Magnusson P. K., Ander-sen P. K., Pontén J., et al.: “Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study”. the Lancet, 2000, 355, 2194-2198.

[7] Naucler P., Ryd W., Törnberg S., Strand A., Wadell G., Hansson B. G., Rylander E., Dillner J.: “HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study”. Br. J. Cancer, 2007, 97, 129-132.

[8] Schiffman M., Clifford G., Buonaguro F.M.: “Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline”. Infect. Agent. Cancer, 2009, 4,

[9] Hwang T.S., Jeong J.K., Park M., Han H.S., Choi H.K., Park T.S.: “Detection and typing of HPV genotypes in various cervical lesions by HPV oligonucleotide microarray”. Gynecol. Oncol., 2003, 90, 51- 56.

[10] Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K. V., et al.: “Epidemiologic Classification of Human Papillo-mavirus Types Associated with Cervical Cancer”. N. Engl. J. Med., 2003, 348, 518-527.

[11] Agarossi A., Ferrazzi E., Parazzini F., Perno C.F., Ghisoni L.: “Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy”. J. Med. Virol., 2009, 81, 529-535.

[12] Wells S.I., Aronow B.J., Wise T.M., Williams S.S., Couget J.A., Howley P.M.: “Transcriptome signature of irreversible senescence in human papillomavirus-positive cervical cancer cells”. Proceedings of the National Academy of Sciences, 2003, 100, 7093-7098.

[13] Hutchinson D.J., Klein K. C.: “Human papillomavirus disease and vaccines”. am. J. Health. Syst. Pharm., 2008, 65, 2105-2112.

[14] de Sanjosé S., Brotons M., Pavón M.A.: “The natural history of hu-man papillomavirus infection”. Best Practice & Research Clinical Obstetrics & Gynaecology, 2018, 47, 2-13.

[15] Berchtold A., Michaud P., Nardelli-Haefliger D., Surís J.: “Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates”. Int. J. Public Health, 2010, 55, 25-34.

[16] Cento V., Ciccozzi M., Ronga L., Perno C.F., Ciotti M.: “Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions”. J. Med. Virol., 2009, 81, 1627-1634.

[17] Rambout L., Hopkins L., Hutton B., Fergusson D.: “Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials”. can. Med. Assoc. J., 2007, 177, 469-479.

[18] de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N., et al.: “Worldwide prevalence and genotype distribu-tion of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis”. the Lancet Infectious Diseases, 2007, 7, 453- 459.

[19] Clifford G.M., Smith J.S., Plummer M., Muñoz N., Franceschi S.: “Human papillomavirus types in invasive cervical cancer world-wide: a meta-analysis”. Br. J. Cancer, 2003, 88, 63-73.

[20] Senapati R., Nayak B., Kar S. K., Dwibedi B.: “HPV genotypes coinfections associated with cervical carcinoma: Special focus on phylogenetically related and non-vaccine targeted genotypes”. Plos one, 2017, 12, e0187844.

[21] Zhang Y., Wang Y., Liu L., Fan Y., Liu Z., Wang Y., et al.: “Awareness and knowledge about human papillomavirus vaccination and its acceptance in China: a meta-analysis of 58 observational studies”. Bmc Public Health, 2016, 16,

[22] Laudadio J.: “Human Papillomavirus Detection”. Adv. Anat. Pathol., 2013, 20, 158-167.

[23] Hong S.R., Kim I.S., Kim D.W., Kim M.J., Kim A.R., Kim Y.O., et al.: “Prevalence and Genotype Distribution of Cervical Human Papillomavirus DNA in Korean Women: A Multicenter Study”. the Korean Journal of Pathology, 2009, 43, 342.

[24] Oyervides-Muñoz M.A., Pérez-Maya A.A., Sánchez-Domínguez C. N., Berlanga-Garza A., Antonio-Macedo M., Valdéz-Chapa L.D., et al.: “Multiple HPV Infections and Viral Load Association in Persistent Cervical Lesions in Mexican Women”. Viruses, 2020, 12, 380.

[25] “Human papillomavirus vaccines: WHO position paper, May 2017”. Wkly. Epidemiol. Rec., 2017, 92, 241-68.

[26] Kim M., No J.H., Song Y.: “Human Papillomavirus Vaccine”. Jour-nal of the Korean Medical Association, 2009, 52, 1180.

[27] Ho G.Y.F., Burk R.D., Klein S., Kadish A.S., Chang C.J., Palan P., et al.: “Persistent Genital Human Papillomavirus Infection as a Risk Factor for Persistent Cervical Dysplasia”. JNCI Journal of the National Cancer Institute, 1995, 87, 1365-1371.

[28] Hong S.H., Lee D.H., Shin H.R.: “Prevalence of Human papillo-mavirus infection in women in South Korea: Incidence of positive HPV DNA and anti-VLPs in residents of Busan city”. Korean. J. Cytopathol., 2004, 15, 17-27.

[29] Wang H.Y., Lee D., Park S., Kim G., Kim S., Han L., et al.: “Diagnostic performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening of Oncogenic Human Papillo-mavirus Infection among Woman with Cervical Lesions in China”. Asian. Pac. J. Cancer. Prev., 2015, 16, 7633-7640.

[30] So K.A., Hong J.H., Lee J.K.: “Human Papillomavirus Prevalence and Type Distribution Among 968 Women in South Korea”. Journal of Cancer Prevention, 2016, 21, 104-109.

[31] Lee D., Department of Pathology, Yonsei University Wonju College of Medicine, Wonju, Korea., Kim S., Park S., Jin H., Kim T. U., et al.: “Human Papillomavirus Prevalence in Gangwon Province Using Reverse Blot Hybridization Assay”. the Korean Journal of Pathology, 2011, 45, 348.

[32] Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S. L., Cain J., et al.: “American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer”. Am. J. Clin. Pathol., 2012, 137, 516.

[33] Kulasingam S.L., Hughes J.P., Kiviat N.B., Mao C., Weiss N.S., Kuypers J. M., et al.: “Evaluation of Human Papillomavirus Testing in Primary Screening for Cervical Abnormalities”. Jama, 2002, 288, 1749.

[34] Kim G., Kim S., Park S., Park S., Lin H., Ren Y., et al.: “Human Papillomavirus Prevalence and Distribution according to Age among Korean and Chinese Women”. Korean Journal of Clinical Laboratory Science, 2015, 47, 259-266.

[35] Magaña-Contreras M., Contreras-Paredes A., Chavez-Blanco A., Lizano M., Cruz-Hernandez Y.D.L., Cruz-Hernandez E.D.L.: “Prevalence of sexually transmitted pathogens associated with HPV infection in cervical samples in a Mexican population”. J. Med. Virol., 2015, 87, 2098-2105.

[36] Stoler M.H.: “Advances in Cervical Screening Technology”. Mod. Pathol., 2000, 13, 275-284.

[37] Wang R., Guo X., Wisman G.B.A., Schuuring E., Wang W., Zeng Z., et al.: “Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China”. Bmc Infect. Dis., 2015, 15.